Article Text

Download PDFPDF
CASE REPORT
Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
  1. Kirsty Le Doare1,
  2. Nathaniel Barber2,
  3. Katja Doerholt3,
  4. Mike Sharland3
  1. 1Department of Paediatrics, Croydon University Hospital, London, UK
  2. 2Department of Paediatrics, St George's Hospital NHS Trust, London, UK
  3. 3Department for Paediatric Infection and Immunology, St George's Hospital NHS Trust, London, UK
  1. Correspondence to Dr Kirsty Le Doare, kirstyledoare{at}gmail.com

Summary

Little evidence is available on the pharmacokinetics of antituberculous medication in premature infants. We report rifampicin (RMP) pharmacokinetics in an extremely premature, low-birthweight female infant born to a mother with known miliary tuberculosis. Intravenous RMP, isoniazid (INH), ciprofloxacin and amikacin were used, as the enteral route was not possible. Area under the curve calculations revealed low average RMP concentrations at doses of 5–10 mg/kg. We review the literature with regard to the dosing regimen and therapeutic drug levels of RMP and INH in premature infants and discuss issues of management. Evidence from this case suggests 10 mg/kg/day is the minimum dose required.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.